Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Monitoring and Treating Patients Coinfected With HBV and HDV
  • CME
  • CE

Loading...
The hepatitis delta virus (HDV) only coexists in patients chronically infected with hepatitis B virus (HBV). Listen to experts discuss steps to take for monitoring and treating both forms of viral hepatitis.
Heiner Wedemeyer, MD
person default
Cihan Yurdaydin, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: March 10, 2022 Expiration: March 9, 2023

Hepatitis delta virus (HDV) only exists in patients with hepatitis B virus (HBV) coinfection. In part 1 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on serologic testing for both HDV and HBV and steps to take in monitoring, treating, and reassessing HBV in patients coinfected with HDV.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Heiner Wedemeyer, MD

Professor and Chairman
Department of Gastroenterology, Hepatology and Endocrinology
Hannover Medical School
Hannover, Germany

Heiner Wedemeyer, MD, has disclosed that he has received consulting fees from AbbVie, Aligos, Altimmune, Biotest, Bristol-Myers Squibb, BTG, Dicerna, Enanta, Gilead Sciences, Janssen, MSD/Merck, MYR GmbH, Roche, and Vir; has received funds for research support from AbbVie, Biotest, Gilead Sciences, MSD/Merck, and Roche; and has served as a clinical trials investigator for AbbVie, Altimmune, Bristol-Myers Squibb, Gilead Sciences, Janssen, MSD/Merck, MYR GmbH, Novartis, and Vir.
Cihan Yurdaydin, MD
Professor and Chief, Department of Gastroenterology and Hepatology
Koç University Medical School
Istanbul, Turkey
Cihan Yurdaydin, MD, has disclosed that he has received consulting fees from Gilead Sciences and fees for non-CME/CE services from AbbVie and Gilead Sciences.

Staff

Sarah Anderson, PharmD
Scientific Director
Sarah L. Anderson, PharmD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, nurse practitioners, physician associates/physician assistants, and other healthcare professionals who provide care for patients with HDV infection.

Goal

The goal of this program is to improve healthcare professionals’ awareness of HDV and the importance of screening in patients with HBV, as well as their competence in treating patients with HBV/HDV coinfection.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 10, 2022, through March 09, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.

Related Content

Drs. Kosh Agarwal and Graham R. Foster discuss linkage to care for patients with HDV, from Clinical Care Options (CCO)

Kosh Agarwal, MD Graham R. Foster, FRCP, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: June 30, 2022 Expired: June 29, 2023

Patient perspectives and key action items to address in clinical settings to reduce HBV care barriers in the United States, from Clinical Care Options (CCO)

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Jennifer Wild, MS, BSN, RN, OCN Released: June 22, 2022

Dr Norah Terrault: missed opportunities for hepatitis delta virus (HDV) testing and how to overcome them, from Clinical Care Options (CCO)

Norah Terrault Headshot Norah Terrault, MD, MPH Released: May 18, 2022

Compare current HBV vaccines and learn the best immunization practices for routine vaccination, including in special situations, from Clinical Care Options (CCO)

Robert G. Gish, MD Released: May 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings